Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma.
about
2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma2014 Korean Liver Cancer Study Group-National Cancer Center Korea practice guideline for the management of hepatocellular carcinomaEvaluation of sorafenib for hepatocellular carcinoma by contrast-enhanced ultrasonography: a pilot studyThymostimulin in advanced hepatocellular carcinoma: a phase II trialPhase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02.A phase I study of sorafenib, oxaliplatin and 2 days of high dose capecitabine in advanced pancreatic and biliary tract cancer: a Wisconsin oncology network study.Phase II Trial of Sorafenib in Combination with Capecitabine in Patients with Hepatocellular Carcinoma: INST 08-20.Proliferation of sphere-forming hepatocellular carcinoma cells is suppressed in a medium without glucose and arginine, but with galactose and ornithine.Eastern Asian expert panel opinion: designing clinical trials of molecular targeted therapy for hepatocellular carcinomaRelationship of ethnicity and overall survival in patients treated with sorafenib for advanced hepatocellular carcinoma.Design and rationale for the non-interventional Global Investigation of Therapeutic DEcisions in Hepatocellular Carcinoma and Of its Treatment with Sorafenib (GIDEON) study.Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.Co-culture of hepatocellular carcinoma cells and human umbilical endothelial cells damaged by SU11274Safety and Efficacy of Sorafenib in Patients with Hepatocellular Carcinoma (HCC) and Child-Pugh A versus B CirrhosisPhase I study of combination chemotherapy using sorafenib and transcatheter arterial infusion with cisplatin for advanced hepatocellular carcinoma.Cryotherapy is associated with improved clinical outcomes of Sorafenib therapy for advanced hepatocellular carcinomaSorafenib in advanced melanoma: a critical role for pharmacokinetics?Cryotherapy is associated with improved clinical outcomes of sorafenib for the treatment of advanced hepatocellular carcinoma.Sorafenib and hepatic arterial infusion chemotherapy for unresectable advanced hepatocellular carcinoma: A comparative studySorafenib suppresses the cell cycle and induces the apoptosis of hepatocellular carcinoma cell lines in serum-free media.Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic ReviewTransarterial chemoembolization with/without cryotherapy is associated with improved clinical outcomes of sorafenib for the treatment of advanced hepatocellular carcinomaHemorrhagic events in hepatocellular carcinoma patients treated with antiangiogenic therapies.Sorafenib combined with cryoablation to treat unresectable hepatocellular carcinomaSorafenib for treatment of hepatocellular carcinoma: a systematic review.The androgen receptor as an emerging target in hepatocellular carcinomaClinical experience and critical evaluation of the role of sorafenib in renal cell carcinoma.Safety and effectiveness of sorafenib in Japanese patients with hepatocellular carcinoma in daily medical practice: interim analysis of a prospective postmarketing all-patient surveillance study.Safety and efficacy of sorafenib therapy in patients with metastatic kidney cancer with impaired renal function.Sorafenib for the treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a prospective multicenter cohort study.Newer treatments for advanced hepatocellular carcinoma.Alternative treatments in advanced hepatocellular carcinoma patients with progressive disease after sorafenib treatment: a prospective multicenter cohort studyAnti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target?2-Deoxyglucose and sorafenib synergistically suppress the proliferation and motility of hepatocellular carcinoma cells.Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus statement.Safety and efficacy of sorafenib in the treatment of hepatocellular carcinoma.Treatment of advanced hepatocellular carcinoma with emphasis on hepatic arterial infusion chemotherapy and molecular targeted therapy.Antiangiogenic treatment in hepatocellular carcinoma: the balance of efficacy and safety.Critical appraisal of the role of sorafenib in the management of hepatocellular carcinoma.Sorafenib for the treatment of unresectable hepatocellular carcinoma.
P2860
Q28392783-BAACC464-6A76-4738-9E7F-DEABB105BC05Q28394414-A07FDEA0-992F-4AAD-A031-EBA86FEDE83DQ30460933-D1169C7C-2099-4FCF-BA6E-9473073649E1Q33325625-B6BE9A7D-F40F-4027-95AE-C9B669A17AEFQ33404027-00A9CE21-92DB-4A21-84B3-ACCC9F471429Q33404952-2E866931-F025-4AF3-A279-1FF679132CB7Q33443438-3C3B1F70-F579-45C6-B97E-58CAB1C5FE5CQ33599232-7516EBF4-E7F6-41C4-8C37-05FE16B09429Q33742856-1C94D324-DD6D-4725-A2E5-BF25068D31C3Q33948042-1355F2F4-8B1D-421B-9988-43B00ED15F9FQ34001687-4C729A5D-2192-4A08-86B9-21654D7EC789Q34200743-70F98D14-6C5B-4D11-B231-BAA80E8BDAF5Q34265415-51B4058A-C5D8-43A0-9160-679025D325E1Q35030418-D3BD3673-F975-46FA-92B9-5F1992D1962BQ35051975-6A64D6E6-5F78-4A97-96AA-53919E0CCD00Q35963024-CFA5B5C2-CA1C-414C-97FC-4D943B9955CFQ36117220-CAD566D3-0CC2-47B1-90A9-5B7F9A50BAA3Q36224737-7C506FF9-B794-4D96-B054-C9C767FD21AAQ36230740-611BE7D5-721B-4DBB-95A6-8E9EDE462F7AQ36244147-AB75E1E8-6C5D-4169-9DBE-7C8A4D39ED59Q36270115-83600491-D91D-4F11-8D6E-894BD7C8692AQ36285672-1A04C346-5A13-45D7-8A5E-D3A98D5451F5Q36644408-C3B4F379-CA95-4378-8F32-FF7EA56C74E6Q36654704-0913FB61-8B04-4514-A31D-338356835ABBQ36680204-8314C19C-C911-4E65-BE61-6F380065CB9CQ37031766-6C4A7D70-CE34-440D-9322-8BE0D01388ABQ37283736-2D84240F-7720-4948-8C7B-47033163E887Q37284654-97DB6BAD-9859-4966-B91F-C0C5604B219AQ37398733-B22C6F7C-B167-4CC4-AC41-71E94FAF3347Q37441574-12407178-6C17-4DB2-8DB7-BBA18D4C7988Q37642185-60814067-0AF8-4FCD-AEBD-AA268DF61495Q37665692-E77A734C-DE24-4159-8AF3-AC567F472A07Q37688711-D3AA1596-D1A6-46F3-9C98-36DDB07A4952Q37701242-6E3A9BB5-DEA9-4165-A0BB-97E158968CFAQ37768896-323629D3-7BAE-4CBB-9272-60B38D9E636AQ37771252-978FD8B0-1FF6-4D71-B1E5-27C0EB0C7730Q38155506-2FBEA982-ECBB-4942-B650-522C347C4ED9Q38160838-8D4C9669-EACB-4D5B-8E81-0F01452ECD10Q38173739-C5C85B68-3CD9-4486-8544-B4F2B6933231Q39952324-F380191D-F9FD-47D2-B510-D3077BE3EA07
P2860
Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma.
@en
Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma.
@nl
type
label
Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma.
@en
Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma.
@nl
prefLabel
Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma.
@en
Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma.
@nl
P2093
P2860
P1433
P1476
Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma.
@en
P2093
Eiichiro Suzuki
Hiroshi Ishii
Junji Furuse
Keiko Nakajima
Kohei Nakachi
Satoshi Shimizu
P2860
P304
P356
10.1111/J.1349-7006.2007.00648.X
P577
2007-10-22T00:00:00Z